Biomarin Pharmaceutical INC: insider trades · United States · SEC (Form 4)

About Biomarin Pharmaceutical INC

BioMarin Pharmaceutical Inc. is a U.S.-based biopharmaceutical company focused on rare and ultra-rare genetic diseases. The shares trade on the NASDAQ under the ticker BMRN in the United States. Headquartered in San Rafael, California, with important operations in Novato, BioMarin was founded in 1997 and originally built its franchise around enzyme technology for genetically defined disorders. Over time, the company evolved into a broader rare-disease platform combining discovery, development, commercialization, and lifecycle expansion of specialized therapies. For investors, BioMarin sits in the quality-growth segment of healthcare: it is not a large diversified pharma group, but a focused specialist with deep scientific expertise and a commercially established rare-disease portfolio. The company’s business model centers on medicines for severe, often lifelong genetic conditions where treatment options are limited and clinical differentiation matters. Its marketed products include VOXZOGO for achondroplasia, PALYNZIQ for phenylketonuria, and a set of established enzyme replacement therapies such as BRINEURA, NAGLAZYME, VIMIZIM, KUVAN, and ALDURAZYME, alongside certain sapropterin-related franchises depending on market and formulation. This portfolio gives BioMarin a meaningful commercial base and supports a recurring-revenue profile, while also leaving room for upside from label expansions, new launches, and pipeline execution. Its competitive position is that of a global rare-disease leader: the company competes on scientific specialization, regulatory know-how, and the ability to operate in small, medically urgent markets where payer access and specialist physician adoption are critical. BioMarin organizes its strategy around three business units: Enzyme Therapies, Skeletal Conditions, and ROCTAVIAN. Geographically, it has a broad international footprint with commercial and operating activity across North America, Europe, Japan, Brazil, and other regions, reflecting the global nature of its rare-disease franchises. Recent developments have been notable. In 2025, BioMarin reported positive data and pursued regulatory expansion for PALYNZIQ in adolescents, completed its acquisition of Inozyme in July 2025 to strengthen its rare-disease portfolio, and later reported solid 2025 operating results together with a growth plan built around portfolio expansion, clinical readouts, and additional indication opportunities. For French-speaking investors, BioMarin offers a niche global healthcare exposure with a mix of established products, pipeline optionality, and strategic M&A-driven growth, all within a U.S.-listed NASDAQ name.